1 2 bis Search Results


bis tris  (Dojindo Labs)
94
Dojindo Labs bis tris
Bis Tris, supplied by Dojindo Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/1+2+bis/Bis-Tris/pm38727928-38-10-13
Average 94 stars, based on 1 article reviews
bis tris - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
bis benzo 15 crown 5 dojindo cas 69271 98 3  (Dojindo Labs)
91
Dojindo Labs bis benzo 15 crown 5 dojindo cas 69271 98 3
Bis Benzo 15 Crown 5 Dojindo Cas 69271 98 3, supplied by Dojindo Labs, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/1+2+bis/Bis/us10335781-113-14-15
Average 91 stars, based on 1 article reviews
bis benzo 15 crown 5 dojindo cas 69271 98 3 - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier
aa 1 110  (Santa Cruz Biotechnology)
90
Santa Cruz Biotechnology aa 1 110
Aa 1 110, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/1+2+bis/(R)-(-)-4%2C12-Bis(diphenylphosphino)-%5B2%2E2%5D-paracyclophane/pmc03897332-147-72-74
Average 90 stars, based on 1 article reviews
aa 1 110 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
atazanavir d 6  (Toronto Research Chemicals)
88
Toronto Research Chemicals atazanavir d 6
Atazanavir D 6, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/1+2+bis/Atazanavir-d6/pmc08067820-357-10-39
Average 88 stars, based on 1 article reviews
atazanavir d 6 - by Bioz Stars, 2026-10
88/100 stars
  Buy from Supplier
paclitaxel  (Chem Impex International)
95
Chem Impex International paclitaxel
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Paclitaxel, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/1+2+bis/Paclitaxel/pmc07596148-84-17-21
Average 95 stars, based on 1 article reviews
paclitaxel - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
acid egta  (Chem Impex International)
95
Chem Impex International acid egta
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Acid Egta, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/1+2+bis/Ethylene+glycol-bis(b-aminoethyl+ether)-N%2CN%2CN'%2CN'-tetraacetic+acid/pm41435878-176-2-10
Average 95 stars, based on 1 article reviews
acid egta - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
4%–12% bis-tris sds-page gels  (LuBioScience GmbH)
90
LuBioScience GmbH 4%–12% bis-tris sds-page gels
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
4%–12% Bis Tris Sds Page Gels, supplied by LuBioScience GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/1+2+bis/4++12++bis+tris+sds+page+gels/10__1172_slash_jci85057-206-0-11
Average 90 stars, based on 1 article reviews
4%–12% bis-tris sds-page gels - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
6,12-bis(4-octylphenyl)-5,11-dihydroindolo[3,2-b]carbazole (3h)  (Arkat USA Inc)
90
Arkat USA Inc 6,12-bis(4-octylphenyl)-5,11-dihydroindolo[3,2-b]carbazole (3h)
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
6,12 Bis(4 Octylphenyl) 5,11 Dihydroindolo[3,2 B]Carbazole (3h), supplied by Arkat USA Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/1+2+bis/trans+11+12+bis++4+5+dihydro+2+sulfanyl+1h+imidazol+1+yl+carbonyl++9+10+dihydro+9+10+ethanoanthracene++23+/10__24820_slash_ark__5550190__p010__557-102-5-2
Average 90 stars, based on 1 article reviews
6,12-bis(4-octylphenyl)-5,11-dihydroindolo[3,2-b]carbazole (3h) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
4-12% bis-tris gels wg1403a  (Introgen Inc)
90
Introgen Inc 4-12% bis-tris gels wg1403a
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
4 12% Bis Tris Gels Wg1403a, supplied by Introgen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/1+2+bis/4+12++bis+tris+gels+wg1403a/us12168057-10861-37-39
Average 90 stars, based on 1 article reviews
4-12% bis-tris gels wg1403a - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
4 to 12% gel  (GenScript corporation)
90
GenScript corporation 4 to 12% gel
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
4 To 12% Gel, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/1+2+bis/4++12++bis+tris+gels+m41210c/pmc09972965-217-27-28
Average 90 stars, based on 1 article reviews
4 to 12% gel - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
12-bis-tha]i2  (ChemPartner)
90
ChemPartner 12-bis-tha]i2
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
12 Bis Tha]I2, supplied by ChemPartner, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/1+2+bis/12+bis+tha+i2/pm26998876-35-0-6
Average 90 stars, based on 1 article reviews
12-bis-tha]i2 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
nativepagetm 3 to 12% (bis-tris, mini protein gels)  (SERVA Electrophoresis)
90
SERVA Electrophoresis nativepagetm 3 to 12% (bis-tris, mini protein gels)
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Nativepagetm 3 To 12% (Bis Tris, Mini Protein Gels), supplied by SERVA Electrophoresis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/1+2+bis/nativepagetm+3+to+12+++bis+tris++mini+protein+gels+/10__1016_slash_j__isci__2025__112135-288-2-5
Average 90 stars, based on 1 article reviews
nativepagetm 3 to 12% (bis-tris, mini protein gels) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), Paclitaxel (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.

Journal: Cellular and Molecular Bioengineering

Article Title: Re-engineering Antimicrobial Peptides into Oncolytics Targeting Drug-Resistant Ovarian Cancers

doi: 10.1007/s12195-020-00626-z

Figure Lengend Snippet: Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), Paclitaxel (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.

Article Snippet: 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), Fmoc-protected amino acids, N,N 0 -diisopropylcarbodiimide (DIC), O-(7-Azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HATU), N,N -dimethylformamide (DMF), and Paclitaxel were purchased from Chem-Impex International, Inc. RPMI-1640, M199, trypsin and EDTA solution, Antibiotic-Antimycotic Solution, ultra-low attachment (ULA) plates, and 1× phosphate buffered saline (PBS) were purchased from Corning.

Techniques: Concentration Assay, Comparison, Activity Assay, Derivative Assay, Cell Culture